Lipid nanoparticles for targeted siRNA delivery - Going from bench to bedside

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3077-3086

  Zatsepin, Timofei S ^a,b,c   Kotelevtsev, Yuri V ^a   Koteliansky, Victor ^a,b  

^a SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

Author keywords

Clinical trial; Lipid nanoparticle; MRNA; RNA therapeutics; SiRNA; Targeted delivery

Indexed keywords

LIPID NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LIPID;

ADRENAL CORTEX CARCINOMA; ANTIVIRAL THERAPY; CHEMICAL STRUCTURE; CLINICAL EFFECTIVENESS; COMPLEX FORMATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOGENICITY; INTERNALIZATION; LIVER CANCER; LYMPH NODE METASTASIS; MELANOMA; NANOPHARMACEUTICS; NEUROENDOCRINE TUMOR; NONHUMAN; OXALOSIS 1; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENE TRANSFER; GENETICS; TRANSLATIONAL RESEARCH;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; NANOPARTICLES; RNA, SMALL INTERFERING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84979082749     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S106625     Document Type: Review

References (74)

1. Vinores SA. Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-268.
2. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Age-Related Macular Degeneration [press release]. 2004 [December 20]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108385.htm. Accessed December 1, 2015.
3. Tse MT. Regulatory watch: Antisense approval provides boost to the field. Nature Rev Drug Disc. 2013;12:179.
4. U.S. Food and Drug Administration. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder [press release]. 2013 [January 29]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm. Accessed December 1, 2015.
5. Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov. 2015;14(12):843-856.
6. Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56: 103-122.
7. Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
8. Chakraborty C, Wen ZH, Agoramoorthy G, Lin CS. Therapeutic microRNA delivery strategies with special emphasis on cancer therapy and tumorigenesis: current trends and future challenges. Curr Drug Metab. 2016;17(5):469-477.
9. Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16(9):543-552.
10. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759-780.
11. Kumar V, Mahato RI. Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res. 2015;32(2):341-361.
12. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967-977.
13. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8): 541-555.
14. Sarett SM, Nelson CE, Duvall CL. Technologies for controlled, local delivery of siRNA. J Control Release. 2015;218:94-113.
15. Fujita Y, Kuwano K, Ochiya T. Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci. 2015;16(3): 5254-5270.
16. Singh Y, Tomar S, Khan S, et al. Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes. J Control Release. 2015;220(Pt A):368-387.
17. Leung AK, Tam YY, Cullis PR. Lipid nanoparticles for short interfering RNA delivery. Adv Genet. 2014;88:71-110.
18. Hope MJ. Enhancing siRNA delivery by employing lipid nanoparticles. Ther Deliv. 2014;5(6):663-673.
19. Wan C, Allen TM, Cullis PR. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res. 2014;4(1): 74-83.
20. Maier MA, Jayaraman M, Matsuda S, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21(8):1570-1578.
21. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010;107(5): 1864-1869.
22. Novobrantseva TI, Borodovsky A, Wong J, et al. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids. 2012;1:e4.
23. Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016; 99(Pt A):129-137.
24. Kumar V, Qin J, Jiang Y, et al. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol Ther Nucleic Acids. 2014;3:e210.
25. Xia Y, Tian J, Chen X. Effect of surface properties on liposomal siRNA delivery. Biomaterials. 2016;79:56-68.
26. Dabkowska AP, Barlow DJ, Hughes AV, Campbell RA, Quinn PJ, Lawrence MJ. The effect of neutral helper lipids on the structure of cationic lipid monolayers. J R Soc Interface. 2012;9(68):548-561.
27. Tenchov BG, MacDonald RC, Siegel DP. Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane “fusogen”. Biophys J. 2006;91(7):2508-2516.
28. Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013;172(3):782-794.
29. Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638-646.
30. Sahay G, Querbes W, Alabi C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013; 31(7):653-658.
31. Gilleron J, Paramasivam P, Zeigerer A, et al. Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res. 2015; 43(16):7984-8001.
32. Osborn MF, Alterman JF, Nikan M, et al. Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res. 2015;43(18):8664-8672.
33. Hou KK, Pan H, Schlesinger PH, Wickline SA. A role for peptides in overcoming endosomal entrapment in siRNA delivery-a focus on melittin. Biotechnol Adv. 2015;33(6 Pt 1):931-940.
34. Hou KK, Pan H, Ratner L, Schlesinger PH, Wickline SA. Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano. 2013;7(10):8605-8615.
35. Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21(5):973-985.
36. Golovin YI, Gribanovsky SL, Golovin DY, et al. Towards nanomedicines of the future: Remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. J Control Release. 2015;219:43-60.
37. Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357-1364.
38. Cohen ZR, Ramishetti S, Peshes-Yaloz N, et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano. 2015;9(2):1581-1591.
39. McCaskill J, Singhania R, Burgess M, et al. Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol Ther Nucleic Acids. 2013;2:e96.
40. Hajdu P, Chimote AA, Thompson TH, Koo Y, Yun Y, Conforti L. Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity. Biomaterials. 2013;34(38):10249-10257.
41. Ramishetti S, Kedmi R, Goldsmith M, et al. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano. 2015;9(7):6706-6716.
42. Weinstein S, Toker IA, Emmanuel R, et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113(1):E16-E22.
43. Ku SH, Jo SD, Lee YK, Kim K, Kim SH. Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev. Epub 2015 Nov 5.
44. Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, Cullis PR. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release. 2014;196:106-112.
45. Landesman-Milo D, Peer D. Transforming nanomedicines from lab scale production to novel clinical modality. Bioconjug Chem. Epub 2016 Jan 20.
46. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172-176.
47. Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther. 2000;11(18):2493-2513.
48. Zhang JS, Liu F, Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev. 2005;57(5): 689-698.
49. Xue HY, Liu S, Wong HL. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond). 2014;9(2):295-312.
50. Kim HP, Han SW, Song SH, et al. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene. 2014;33(25): 3334-3341.
51. Zhou D, Zhang YI, Liang D, et al. Effect of combination therapy of siRNA targeting growth hormone receptor and 5-fluorouracil in hepatic metastasis of colon cancer. Oncol Lett. 2015;10(6):3505-3509.
52. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729): 1896-1905.
53. Yuen MF, Chan HL, Given BD, Hamilton J, Schluep T, David L. Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection. Hepatology. 2015;62: 1385A.
54. Yuen MF, Chan HL, Given BD, et al. ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B. Hepatology. 2015;62:1385A.
55. Gish RG, Yuen MF, Chan HL, et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res. 2015;121:97-108.
56. Beg MS, Brenner A, Sachdev J, et al. Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. Mol Cancer Ther. 2015;14:C43.
57. Liu X. Targeting polo-like kinases: a promising therapeutic approach for cancer treatment. Transl Oncol. 2015;8(3):185-195.
58. Ramanathan RK, Hamburg SI, Borad MJ, et al. A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. Cancer Res. 2013;73(8 Suppl): LB-289.
59. Abrams M, Ganesh S, Ying B, et al. EnCore-LNP mediated tumor delivery of MYC and CTNNB1 dicer substrate RNAs (DsiRNAs). Mol Cancer Res. 2015;13(10 Suppl):B20.
60. Ganesh S, Ying B, Koser M, et al. Systemic delivery of CTNNB1 dicer-substrate siRNAs (DsiRNAs) leads to efficient oncogene silencing in diverse tumor types of extra hepatic origin. Cancer Res. 2015; 75(15 Suppl):3533.
61. Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910-6918.
62. Shen H, Rodriguez-Aguayo C, Xu R, et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013;19(7):1806-1815.
63. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108-119.
64. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase 1 trial. Lancet. 2014;383(9911):60-68.
65. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71-77.
66. Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009; 284(42):28856-28864.
67. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
68. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen a. loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41.
69. Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479-1490.
70. Wang X, Wang D, Shan Z. Clinical and genetic analysis of a family diagnosed with familial hypobetalipoproteinemia in which the proband was diagnosed with diabetes mellitus. Atherosclerosis. 2015;239(2):552-556.
71. Tikka A, Soronen J, Laurila PP, Metso J, Ehnholm C, Jauhiainen M. Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation. Biosci Rep. 2014;34(6):e00160.
72. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819-829.
73. Butler JS, Chan A, Costelha S, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid. 2016; 23(2):1-10.
74. Haase N, Foster D, Bercher J, et al. RNAi therapeutics targeting human angiotensinogen (hAGT) ameliorate preeclamptic sequelae in an established transgenic rodent model for preeclampsia. Hypertension. 2014;64:A666.